Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis
JAMA Dermatology · 2025
DOI: 10.1001/jamadermatol.2024.4796 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA Dermatology, 2025. Verfasst von Sonja Ständer und 26 weiteren Autor:innen. Beteiligte Einrichtung: Center for Chronic Pruritus and Department for Dermatology, University Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Prurigo, Antibodies, Monoclonal, Humanized, Pruritus. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Prurigo nodularis (PN) is a chronic and debilitating skin condition, characterized by intense itch with multiple nodular lesions. Nemolizumab demonstrated significant improvements in itch and skin nodules in adults with moderate to severe PN in a previous 16-week phase 3 study (OLYMPIA 2).
Objective
To assess the efficacy and occurrence of adverse events in adults with moderate to severe PN treated with nemolizumab vs those receiving placebo. Design, Setting, and Participants OLYMPIA 1 was a multicenter, placebo-controlled, phase 3 randomized clinical trial, conducted from August 2020 to March 2023 at 77 centers across 10 countries in adults with moderate to severe PN (at least 20 nodules and an Investigator’s Global Assessment [IGA] score ≥3) and Peak Pruritus Numerical Rating Scale (PP-NRS) score of at least 7.0; consisted of screening (up to 4 weeks), 24-week treatment, and 8-week follow-up periods.
Interventions
Patients were randomized (2:1) to nemolizumab monotherapy, 30 mg or 60 mg (depending on baseline weight of less than 90 kg vs 90 kg or greater, respectively), or matching placebo administered every 4 weeks for 24 weeks. Main Outcomes and Measures The primary end points were the proportion of patients with itch response (≥4-point improvement from baseline in weekly average PP-NRS) and IGA success (score of 0/1 [clear/almost clear] and 2-grade or more improvement from baseline) at week 16.
Results
Of 286 patients (mean [SD] age, 57.5 [13.0] years; mean [SD] body weight, 85.0 [20.7] kg; 166 [58.0%] female), 190 were randomized to receive nemolizumab, and 96 were randomized to placebo. A significantly greater proportion of patients assigned to nemolizumab vs placebo achieved itch response (111/190 [58.4%] vs 16/96 [16.7%]; Δ, 40.1% [95% CI, 29.4%-50.8%]; P < .001) and IGA success (50/190 [26.3%] vs 7/96 [7.3%]; Δ, 14.6% [95% CI, 6.7%-22.6%]; P = .003) at week 16. At week 24, the proportion of patients with itch response was 58.3% vs 20.4% (Δ, 38.7% [95% CI, 27.5%-49.9%]) in the ad hoc analysis, and IGA success was 58/190 (30.5%) vs 9/96 (9.4%) (Δ, 19.2% [95% CI, 10.3%-28.1%]) in the nemolizumab-treated vs placebo group. During the treatment period, 134 patients (71.7%) receiving nemolizumab vs 62 patients (65.3%) receiving placebo had at least 1 adverse event; most events were of mild to moderate severity. Conclusions and Relevance In this randomized clinical trial, nemolizumab monotherapy led to clinically meaningful and statistically significant improvements in core signs and symptoms of PN. Trial Registration ClinicalTrials.gov Identifier: NCT04501666
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Chronic Pruritus and Department for Dermatology, University Hospital Münster, Münster, Germany.
- Miami Itch Center, Miller School of Medicine at the University of Miami, Miami, Florida.
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.
- Department of Dermatology, University of Rzeszów, Rzeszów, Poland.
- Department of Dermatology, Medical University of Toulouse, Toulouse, France.
- Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Zitieren
APA
Ständer, S., Yosipovitch, G., Legat, F. J., Reich, A., Paul, C., Simon, D., Naldi, L., Metz, M., Tsianakas, A., Pink, A., Fage, S., Micali, G., Weisshaar, E., Sundaram, H., Metelitsa, A., Augustin, M., Wollenberg, A., Homey, B., Fargnoli, M. C., …, & OLYMPIA 1 Investigators (2025). Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.4796
Vancouver
Ständer S, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis. JAMA Dermatology. 2025. doi:10.1001/jamadermatol.2024.4796
BibTeX
@article{Stnder2025,
author = {Ständer, Sonja and Yosipovitch, Gil and Legat, Franz J and Reich, Adam and Paul, Carle and Simon, Dagmar and Naldi, Luigi and Metz, Martin and Tsianakas, Athanasios and Pink, Andrew and Fage, Simon and Micali, Giuseppe and Weisshaar, Elke and Sundaram, Hema and Metelitsa, Andrei and Augustin, Matthias and Wollenberg, Andreas and Homey, Bernhard and Fargnoli, Maria Concetta and Sofen, Howard and Korman, Neil J and Skov, Lone and Chen, Xiaoxiao and Jabbar-Lopez, Zarif K and Piketty, Christophe and Kwatra, Shawn G and OLYMPIA 1 Investigators, OLYMPIA 1 Investigators},
title = {Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis},
journal = {JAMA Dermatology},
year = {2025},
doi = {10.1001/jamadermatol.2024.4796}
}
EUVIMED